(Q53600128)

16 May 2018

title

Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. (English)

1 reference

16 May 2018

main subject

phase II clinical trial

0 references

1 reference

Donald L Trump

1

1 reference

16 May 2018

Douglas M Potter

2

1 reference

16 May 2018

Josephia Muindi

3

1 reference

16 May 2018

Adam Brufsky

4

1 reference

16 May 2018

Candace S Johnson

5

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 May 2006

1 reference

16 May 2018

published in

Cancer

1 reference

16 May 2018

volume

106

1 reference

16 May 2018

page(s)

2136-2142

1 reference

16 May 2018

issue

10

1 reference

16 May 2018

The role of the vitamin D endocrine system in health and disease

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Vitamin D treatment in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21890

7 January 2021

Identifiers

DOI

10.1002/CNCR.21890

1 reference

16 May 2018

PubMed ID

16598750

1 reference

16 May 2018